Study on the effects and mechanism of wheat and corn germ blend oil on antioxidation and immune regulation of dyslipidemia population based on intestinal flora

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200059288

Enrollment

Unknown

Registered

2022-04-28

Start date

2023-05-01

Completion date

Unknown

Last updated

2024-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lipid abnormality

Interventions

Intervention group :Wheat and corn germ blend oil

Control group:Peanut oil

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. The basic data of the screening study subjects come from the internal physical examination data of Yiga Health Management Company, and the second physical examination will be conducted for the study subjects after the screening of the qualified subjects. According to the "Guidelines for Prevention and Control of Dyslipidaemia in Adults in China" (Revised Edition, 2016), and in accordance with the recommendations for the appropriate level of the lipid composition and the abnormal cut-off point of China's population, when serum TC =5.2mmol/L and/or TG =1.7 When serum TC =5.2mmol/L and/or TG =1.7mmol/L and/or LDL-C =3.4mmol/L and/or HDL-C <1.0mmol/L, it is regarded as dyslipidaemia; 2. BMI range: 18.5-23.9kg/m2; 3. Age =18 years old; 4. Ethnicity: Han Chinese.

Exclusion criteria

Exclusion criteria: 1. Pregnant women, lactating mothers; 2. diabetes, coronary heart disease people, hyperthyroidism patients, patients with malignant tumours, asthma, etc. In addition to dyslipidaemia suffering from other chronic diseases; 3. alcoholics; 4. postoperative patients; 5. endocrine disease patients and those who receive hormone therapy; 6. long-term use of antibiotics crowd; 7. long-term use of probiotics, prebiotics and other agents to change the function of intestinal flora of the population; 8. the use of immunomodulatory preparations of the population.

Design outcomes

Primary

Measure	Time frame
total cholesterol;triglyceride;low density lipoprotein cholesterol;high density lipoprotein cholesterol;leptin;Transforming growth factor ß;reactive oxygen species;malondialdehyde;glutathione;waist circumference;hip measurement;natural killer cell (NKC);Immunoglobulin A;Immunoglobulin E;Immunoglobulin G;Immunoglobulin M;Complement C3;Tumour necrosis factor-a;	—

Secondary

Measure	Time frame
interleukin-6;interleukin-8;interleukin-10;helper T cell;blood pressure;body mass index (BMI);	—

Countries

China

Contacts

Public ContactGuiju Sun

Department of Nutrition and Food Hygiene, School of Public Health, Southeast University

gjsun@seu.edu.cn+86 139 5192 8860

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026